Medical Publication Strategy and Planning
This domain tests whether you can convert clinical evidence and stakeholder needs into a defensible, resourced publication plan. Expect questions on gap analysis, publication steering committees, audience segmentation, channel selection, timing, budgeting, and metrics.
Build the plan from evidence, not a wish list
- Begin with a systematic landscape and gap analysis: what is already published, what congress data exist, and which evidence gaps matter to prescribers, payers, patients, regulators, and guideline developers.
- Map every planned output to a specific data source (study report, CSR, registry analysis) and a named audience. A plan that lists manuscripts without this mapping is a wish list, not a strategy.
- Use a publication steering committee or publications committee with a written charter to approve the plan, resolve authorship disputes, and oversee disclosure.
- Cover the whole evidence lifecycle: primary and secondary analyses, negative and inconclusive studies, trial registration, results posting, plain-language summaries, and data-sharing statements.
Sequence and resource the plan
- Tie milestones to data lock, congress abstract deadlines (often months before the meeting), journal lead times, and regulatory milestones. Avoid sequencing that could look like pre-approval promotion.
- Budget for medical writing, open-access fees, congress fees, permissions, patient-facing summaries, and vendor oversight, not only journal submission charges.
- Choose metrics that reflect reach and use: downloads, citations, guideline or policy uptake, HCP engagement, and patient accessibility. Impact factor alone is a weak planning KPI.
Worked example
A Phase 2b program has a positive primary endpoint but a non-significant key secondary endpoint. The team proposes one manuscript reporting only the primary result and an abstract omitting the secondary. Reasoning: the plan must report the study completely and in balance. A primary manuscript should present the full efficacy and safety profile, identify the secondary endpoint as not met, and follow the relevant reporting guideline. The abstract should match the manuscript data. Registration and results disclosure should be scheduled independently of whether the result is attractive.
Traps that cost marks
- Treating the plan as a static document rather than a living, version-controlled strategy.
- Planning only positive or high-impact outputs and ignoring negative data.
- Assigning authorship after drafting has begun.
- Forgetting patient-facing summaries, data-sharing statements, or registry disclosure.
- Letting commercial goals dictate scientific sequencing.
- Using journal impact factor as the sole success measure.